Dr Sam Fazeli joins Arecor as Non-Executive Director


Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, is pleased to announce the appointment of Dr Sam Fazeli as Non-Executive Director of the Company.

Add This Share Buttons

Dr Fazeli is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London.  He specialises in global pharmaceuticals.

Commenting on the appointment, Dr Sarah Howell, CEO of Arecor Limited, said, "We are delighted to welcome Sam to the Board.  He brings with him a global perspective across biologics and pharmaceuticals, which will deliver valuable insights for Arecor as we accelerate our dual strategy of developing proprietary superior diabetes products and forging deep multi-product alliances with biopharmaceutical companies to enhance their products”.

Sam Fazeli added, “I am excited by Arecor’s potential. The diabetes space is one of major medical need, where there are few innovator companies and limited new product avenues.  Arecor’s technology has allowed it to adopt a novel approach that has generated impressive data on its pipeline products - these are now well set to progress towards clinical development.  Furthermore, I believe Arecor’s successful exploitation of technology to deliver superior formulations of biosimilar products for its pharmaceutical customers will help differentiate biosimilar pipelines from competition and in so doing, offer patients access to more affordable versions of key therapeutics.  I very much look forward to joining the board and making Arecor a success”.

Dr Fazeli brings over nineteen years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research.  Before transitioning to investment banking, he was a research scientist for seven years. Dr Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a first degree from Cardiff University, and a Ph.D. in pharmacology from the University of London.

Dr Andy Richards, CBE, Chairman of Arecor Limited, further commented, "Sam will add substantive independent knowledge, insight and ambition to the Board of Arecor. He brings with him, not only a depth of experience in pharmaceuticals and bioetchnology, but also an understanding of public and capital markets that will be important for future corporate plans. My fellow directors and I are relishing the opportunity to work with him.”



For more information, please contact:

Arecor Limited


Dr Sarah Howell, Chief Executive

Tel: +44 (0) 1223 426 060

Peckwater PR


Tarquin Edwards

Tel: +44 (0) 7879 458 364


About Arecor

Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides.  Arecor's product portfolio also includes:

  • Stable aqueous glucagon for emergency and artificial pancreas use,
  • Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
  • Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices.

In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.



Advancing today's therapies to enable healthier lives.

Arecor Therapeutics Plc